Medicare Enrolled
Dr. Tammy Roque, MD
Medical Oncology · Sherman, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Roque from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Roque? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Roque
Dr. Tammy Roque is a medical oncology in Sherman, TX, with 19 years in practice. Based on federal Medicare data, Dr. Roque performed 47,208 Medicare services across 2,608 unique beneficiaries.
Between the years covered by Open Payments, Dr. Roque received a total of $3,439 from 45 pharmaceutical and/or device companies across 118 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Roque is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 21% volume in TX$ $3,439 industry payments
Medicare Practice Summary
Medicare Utilization ↗47,208
Medicare services
Top 21% in TX for medical oncology
2,608
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,485 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 14,280 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 7,300 | $44 | $137 |
| Iron sucrose injection (Venofer) | 5,600 | $0 | $2 |
| Oxaliplatin chemotherapy injection | 5,200 | $0 | $33 |
| Contrast dye for imaging (iodine-based) | 2,645 | $0 | $3 |
| Anti-nausea injection (fosaprepitant) | 2,400 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 1,620 | $19 | $67 |
| Complete blood count (CBC) with differential | 1,044 | $8 | $36 |
| Blood draw (venipuncture) | 1,036 | $8 | $20 |
| Dexamethasone injection (steroid) | 1,010 | $0 | $1 |
| Comprehensive metabolic blood panel | 795 | $10 | $64 |
| Injection, granisetron hydrochloride, 100 mcg | 470 | $0 | $24 |
| Office visit, established patient (30-39 min) | 437 | $90 | $368 |
| Office visit, established patient (20-29 min) | 390 | $60 | $250 |
| Anti-nausea injection (Aloxi/palonosetron) | 270 | $1 | $114 |
| Injection, leucovorin calcium, per 50 mg | 245 | $3 | $25 |
| Injection, fluorouracil, 500 mg | 236 | $2 | $13 |
| Administration of chemotherapy into vein, 1 hour or less | 187 | $98 | $707 |
| Ferritin level test (iron stores) | 130 | $13 | $60 |
| Iron level test | 128 | $6 | $27 |
| Iron binding capacity test | 128 | $9 | $35 |
| Injection of additional new drug or substance into vein | 109 | $12 | $108 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 107 | $22 | $157 |
| Injection, zoledronic acid, 1 mg | 105 | $6 | $431 |
| Injection, carboplatin, 50 mg | 96 | $2 | $300 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 88 | $47 | $313 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 85 | $55 | $211 |
| Lactate dehydrogenase (enzyme) level | 75 | $6 | $31 |
| Blood creatinine level | 58 | $5 | $31 |
| Irrigation of implanted venous access drug delivery device | 55 | $19 | $114 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 55 | $132 | $3,675 |
| Drug injection, under skin or into muscle | 54 | $11 | $96 |
| Microscopic examination for white blood cells with manual cell count | 49 | $4 | $22 |
| Complete blood count (CBC), automated | 49 | $6 | $34 |
| Administration of additional new drug or substance into vein, 1 hour or less | 49 | $49 | $344 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 43 | $90 | $657 |
| Administration of chemotherapy into vein, each additional hour | 40 | $21 | $161 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 39 | $1,115 | $4,802 |
| CT scan of chest, without contrast | 38 | $47 | $686 |
| Magnesium level test | 35 | $7 | $29 |
| Injection, diphenhydramine hcl, up to 50 mg | 34 | $1 | $7 |
| Ct scan of chest with contrast | 31 | $59 | $821 |
| Manual urinalysis test with examination using microscope, non-automated | 29 | $4 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 29 | $15 | $94 |
| Telephone medical discussion with physician, 5-10 minutes | 29 | $41 | $143 |
| Unclassified drugs | 29 | $1 | $8 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 28 | $20 | $128 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 28 | $339 | $1,722 |
| Carcinoembryonic antigen (cea) protein level | 26 | $19 | $99 |
| PSA test (prostate cancer screening) | 24 | $18 | $94 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 24 | $124 | $500 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $26 | $145 |
| Administration of additional new drug or substance into vein using push technique | 19 | $40 | $289 |
| CT scan of abdomen and pelvis with contrast | 18 | $175 | $1,067 |
| Infusion, normal saline solution , 1000 cc | 18 | $2 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $16 | $100 |
| Hospital follow-up visit, high complexity | 14 | $91 | $357 |
| Infusion into a vein for hydration, each additional hour | 12 | $10 | $75 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
30.9% high complexity
59.1% medium
10.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,439
Total received (2018-2024)
Avg $491/year across 7 years
Bottom 48% in TX for medical oncology
45
Companies
118
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,043 (88.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$396 (11.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$822
2023$660
2022$319
2021$47
2020$528
2019$675
2018$388
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$273
Astellas Pharma US Inc
$251
GlaxoSmithKline, LLC.
$250
Merck Sharp & Dohme Corporation
$214
Novartis Pharmaceuticals Corporation
$196
Inari Medical, Inc.
$150
GENZYME CORPORATION
$127
AstraZeneca Pharmaceuticals LP
$125
Seagen Inc.
$124
Genentech USA, Inc.
$124
PFIZER INC.
$114
Stemline Therapeutics Inc.
$105
Celgene Corporation
$94
Pharmacyclics LLC, An AbbVie Company
$90
Daiichi Sankyo Inc.
$86
SANOFI-AVENTIS U.S. LLC
$84
Blueprint Medicines Corporation
$84
Lilly USA, LLC
$75
Exelixis Inc.
$67
Incyte Corporation
$57
EMD Serono, Inc.
$55
PharmaEssentia USA Corporation
$52
Bayer HealthCare Pharmaceuticals Inc.
$48
SOBI, INC
$45
Tempus AI, Inc
$43
ABBVIE INC.
$39
Amgen Inc.
$38
Merck Sharp & Dohme LLC
$32
Medtronic, Inc.
$32
BeiGene USA, Inc.
$31
Gilead Sciences, Inc.
$30
Agios Pharmaceuticals, Inc.
$30
ADC Therapeutics America, Inc.
$29
Rigel Pharmaceuticals, Inc.
$28
G1 Therapeutics, Inc.
$25
Janssen Biotech, Inc.
$25
Kite Pharma, Inc.
$25
AbbVie, Inc.
$25
Acrotech Biopharma LLC
$24
Aveo Pharmaceuticals, Inc.
$19
Eisai Inc.
$18
Takeda Pharmaceuticals U.S.A., Inc.
$16
EISAI INC.
$14
TerSera Therapeutics LLC
$13
Medtronic USA, Inc.
$12
Top 3 companies account for 22.5% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AYVAKIT · BELEODAQ · BESREMI · BRUKINSA · Bavencio · CALQUENCE · COSELA · Cabometyx · DOPTELET · Doptelet · ELITEK · EMPLICITI · EPKINLY · ERLEADA · Enhertu · FLOWTRIEVER CATHETER · FOTIVDA · FRUZAQLA · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · ONUREG · OPDIVO · OSTEOCOOL RF ABLATION · OSTEOCOOL RF ABLATION SYSTEM · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · Padcev · Perjeta · Pomalyst · Revlimid · Rezlidhia · S · SARCLISA · SCEMBLIX · SPRYCEL · Stivarga · TAGRISSO · TECENTRIQ · TIBSOVO · VERZENIO · Venclexta · XALKORI · XTANDI · Xofigo · Yescarta · ZEJULA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $7 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
2.9
County median income
$70,455
Nearest hospital
BAYLOR SCOTT AND WHITE SURGICAL HOSPITAL AT SHERMA
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Roque is a mixed practice specialist, with above-average Medicare volume (top 21% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Roque experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Roque performed 14,280 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Roque receive payments from pharmaceutical companies?
Yes. Dr. Roque received a total of $3,439 from 45 companies across 118 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Roque's costs compare to other medical oncologys in Sherman?
Dr. Roque's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Roque) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Sherman
Browse medical oncologys in Sherman ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology